Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study.

Authors

Christine B. Ambrosone, Roswell Park Cancer Institute
Kathleen M. Darcy, Roswell Park Cancer Institute, Buffalo, NY
Thomas C. Krivak, University of Pittsburgh
Deborah K. Armstrong, Johns Hopkins University
Michael A. Bookman, Arizona Cancer Center, Tucson, AZ
Warren Davis, University of Pittsburgh
Hua Zhao, Roswell Park Cancer Institute
Kirsten Moysich, Roswell Park Cancer Institute
Holly Gallion, Pikeville Medical Center
Julie A. DeLoia, George Washington University

Document Type

Journal Article

Publication Date

3-2012

Journal

Gynecologic Oncology

Volume

Volume 124, Issue 3

Inclusive Pages

575-581

Keywords

ATP-Binding Cassette Transporters--genetics; Antineoplastic Combined Chemotherapy Protocols--therapeutic use; Multidrug Resistance-Associated Proteins--genetics; Neoplasm Proteins--genetics; Ovarian Neoplasms--drug therapy; Ovarian Neoplasms--genetics; P-Glycoprotein--genetics

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Tian, C., Ambrosone, C. B., Darcy, K. M., Krivak, T. C., Armstrong, D. K., Bookman, M. A., . . . Deloia, J. A. (2012). Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A gynecologic oncology group study. Gynecologic Oncology, 124(3), 575-581.

Peer Reviewed

1

Open Access

1